Long-Acting Relief in Allergic Rhinitis: A Clinical Update on Dual Molecule Approach

Allergic rhinitis (AR) is a pervasive health burden affecting over 400 million individuals globally, presenting with a wide range of nasal symptoms such as rhinorrhea, sneezing, itching, congestion, postnasal drip (PND), snoring, mouth breathing, and loss of taste or smell, as well as ocular symptoms including itching, redness, tearing, and wet eyes. [1] Nasal congestion, occurring in approximately 90% of patients, is among the most bothersome symptoms and the leading contributor to rhinitis-related sleep disturbances. [2]

Symptom relief is the cornerstone of AR management. Pharmacological therapies that reduce culprit inflammatory mediators can alleviate nasal congestion, while also improving sleep quality and overall quality of life. However, monotherapy often fails due to incomplete symptom control and poor adherence. The fexofenadine-pseudoephedrine combination addresses this gap by targeting both histaminic and congestive symptoms while maintaining cognitive function through its non-brain-interfering antihistamine component. [3]

Tackling Nasal Congestion Allergic Rhinitis – How a Dual Approach Works?

Although histamine is the primary mediator underlying most symptoms of AR, it is not the predominant mediator underlying nasal congestion. Mast-cell mediators, particularly leukotrienes (LTC4, LTD4, and LTE4) and prostaglandin D2, act together to cause nasal congestion. Therefore, combinations of an oral antihistamine with an oral decongestant are employed to control the broad spectrum of AR symptoms, including pruritus, rhinorrhoea, and nasal congestion. Second-generation oral antihistamines are fast-acting, long-lasting, and well-tolerated, ensuring better compliance. [4] Oral decongestants, particularly in extended-release formulations, provide sustained relief of nasal congestion with long-lasting effects (12-24 hours) by activating adrenergic receptors, which cause vasoconstriction in the nasal mucosa, thereby improving nasal airflow and reducing mucosal edema.[5]

The Fexofenadine-Pseudoephedrine Combination: Newer Option in India

Fexofenadine is an inverse agonist that exhibits antihistaminic effects by binding to the inactive form. It occupies more than 90% of histamine H1 receptors in less than 1 h, with residence time for binding the human H1 receptor >100-fold higher than diphenhydramine and very rapid binding kinetics. [6] Importantly, fexofenadine is a non-brain-interfering antihistamine that preserves cognitive and psychomotor functions, established even at higher than recommended doses. Pseudoephedrine, the most commonly used decongestant in combination products, is recognized as an effective option for relieving nasal congestion, with a proven safety profile. It causes narrowing of the blood vessels of swollen nasal mucous membranes, reducing tissue hyperaemia, oedema, and nasal congestion, facilitating drainage of sinus secretions. The combination formulation (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) is indicated for adults and children aged 12 years and older for the relief of symptoms associated with allergic rhinitis.[4]

Clinical Evidence on Fexofenadine and Pseudoephedrine Combination

Fexofenadine and Pseudoephedrine Combination Edge in Rhinitis Relief: A multicenter, double-blind, parallel-group study randomized patients (n=651) with seasonal AR (allergic to ragweed) to receive fexofenadine 60mg twice daily, sustained-release pseudoephedrine 120mg twice daily, or a combination of the two drugs twice daily for 2 weeks. Combination therapy significantly reduced histamine-mediated symptoms—sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes (2.32 vs 1.42, P<0.0001)—more than pseudoephedrine alone and reduced nasal congestion (0.56 vs 0.36, P<0.0005) more than fexofenadine alone. No serious adverse events or clinically significant ECG changes were noted. Combination therapy of fexofenadine plus pseudoephedrine provided superior relief of both histamine-mediated symptoms and nasal congestion compared to monotherapy. [7]

Fexofenadine and Pseudoephedrine Combination on Nasal Airflow & Symptom Relief in Rhinitis: A randomized, parallel-group study compared a combination of fexofenadine 60mg and pseudoephedrine 120mg with fexofenadine 60mg alone over 8 hours, using rhinomanometry and Visual Analog Scale assessments at 30-minute intervals. The combination of fexofenadine plus pseudoephedrine showed significantly greater improvement than fexofenadine alone in nasal airflow (p<0.001), with onset at 30 minutes (+53.2 cm³/s), peak effect at 180 minutes (+128.0 cm³/s, p<0.01 vs baseline), and sustained improvement through 480 minutes (+98.1 cm³/s, p<0.01 vs baseline). This showed that the combination of fexofenadine plus pseudoephedrine effectively reduced AR symptoms. [8]

Clinical Call to Action: Choose a fast-acting and long-lasting combination for allergies with nasal congestion.

Fexofenadine & Pseudoephedrine: Guidelines’ View

Key Takeaways

• Allergic rhinitis is a significant global health burden; nasal congestion is one of the most bothersome symptoms and the leading cause of rhinitis-related sleep disturbances, affecting nearly 90% of AR patients.
• Mast-cell mediators, such as leukotrienes and prostaglandin D₂, drive nasal congestion, making a combination of second-generation antihistamines and decongestants an effective consideration for broader symptom control in allergic rhinitis.
• Fexofenadine, a non-brain-interfering antihistamine, provides fast-acting, long-lasting relief without affecting cognitive or psychomotor function, complemented with pseudoephedrine, which effectively reduces nasal congestion.
• Combination therapy of fexofenadine and pseudoephedrine delivers superior and sustained relief of both histamine-mediated symptoms (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) and nasal congestion compared to monotherapy.

MAT-IN-2501153 v1.0 10/25